Immunotherapy using antibodies that target the checkpoint proteins CTLA-4, PD-1, and PD-L1 is improving the treatment of some cancers; however, combination therapies that will provide broader and more sustained clinical responses are desired. The gene discussed is CTLA4; the disease is cancer.